MMC Ventures’ Post

The investigation of subphenotypes in hospitalized COVID-19 patients has been a focal point of research. However, many studies have assumed heterogeneity in patient populations, potentially leading to misleading findings. A recent biomarker analysis challenges this assumption, providing evidence for host response homogeneity among patients with COVID-19. This finding underscores the importance of reevaluating our understanding of patient diversity in the context of the disease. #COVID19 #BiomarkerAnalysis #PatientDiversity 🦠🔬

🔬 Exciting Research Alert! 🔬 A groundbreaking study aims to identify biomarkers for Inflammatory Bowel Disease (IBD), a chronic condition affecting over 540,000 people in the UK. This research is a significant step towards personalized medicine, aiming to develop more targeted and effective treatments for IBD patients. Understanding specific biomarkers associated with IBD will pave the way for tailored therapies, improving patient outcomes and quality of life. Stay tuned for more updates on this innovative research! For more details, check out the full article here: https://lnkd.in/gWxp28zD #IBD #PersonalizedMedicine #Healthcare #MedicalResearch #Biomarkers #Innovation #PatientCare #ChronicIllness #HealthScience

Researchers have developed a new blood test that takes a deeper look at the proteins in blood plasma, revealing biomarkers that enable researchers and physicians to detect diseases sooner: https://lnkd.in/eN25fWKF #diagnostics #healthtech #healthcare

Biological markers (also known as biomarkers) are substances in the body that can give researchers and doctors information about a person’s health. 🔬 Discover how biomarkers can expand what we know about Parkinson’s disease & how biomarkers can possibly lead to earlier diagnosis: https://lnkd.in/gPjDK5K7

I am pleased to share our latest publication in BMC Research Notes, where we examine the roles of galectin-3 and irisin as biomarkers in predicting severe COVID-19 outcomes. Galectin-3 emerged as a significant predictor, while irisin shows potential for future research. These findings may guide the development of targeted approaches for managing high-risk patients. Read more here:  https://lnkd.in/deDqyQv4  #COVID19 #Biomarkers #ClinicalResearch

🔬 Excited to share our latest article on predicting the clinical course of Adult-onset Still's Disease (AoSD). 🌟 This study is incredibly special to me as it marks the end of my Internal Medicine residency before I fully dedicate myself to Infectious Diseases. It also stands as the highlight of my training in using AI for scientific research. 💡 Using advanced AI, we've delved into the clinical heterogeneity of AoSD, identifying patient profiles through routine biomarkers. These profiles help predict the disease's course, whether it be monocyclic, polycyclic, or chronic articular, based on levels of ferritin, ESR, leukocytes, and CRP. 🩺 Our study highlights the transformative role of the k-medoids algorithm, significantly improving the personalization of treatment for AoSD. With this technology, we can create specific and efficient therapies for different patterns of the disease, paving the way towards medicine where personalized diagnosis and treatment change the management of autoinflammatory diseases. 🚀 🌐 #AoSD #ClinicalResearch #PersonalizedMedicine #ArtificialIntelligence #AutoinflammatoryDiseases

Struggling to find a diagnosis for a rare disease? This article explores groundbreaking advancements in #raredisease diagnostics, including #genomics, #AI, and #telemedicine. Discover how these innovations are paving the way for precision medicine and leading to a brighter future for patients. ➡ https://lnkd.in/gZbeTnQu #rarediseasediagnostics #genomicsequencing #biomarkerdiscovery #precisionmedicine #personalizedtreatments #healthcareindustry #europeanhhm

A study presented at #CHEST2024 reveals that while ICIs improve survival in metastatic #lungcancer, they also increase risks of blood clots like DVT and PE, especially with PD-1 inhibitors. Full study can be found here - https://bit.ly/3VqfIqS This highlights the need for tools like our upcoming PROphetirAE® test, which uses #AI and #biomarkers to identify patients at higher risk of immune-related adverse events. This will allow physicians to enable safer personalized care for their patients before administering ICIs. Learn more about PROphetirAE® here: https://bit.ly/3ZBx1HJ #Immunotherapy #AdverseEvents #HealthcareInnovation #IndustryNews

Single-microglia #transcriptomic transition networks and real-world patient data to identify ketorolac as a repurposable therapy for #Alzheimer’s disease. A breakthrough in drug repurposing and precision medicine. #Genomics #DrugRepurposing #TranslationalMedicine #PrecisionMedicine” #ClevelandClinc

Alzheimer's disease diagnosis is on the brink of transformation with blood-based biomarker (BBM) tests. 🧠 🩸 Simpler, cheaper, and less invasive than current methods, blood biomarkers—detectable through a simple blood sample—are proving to be as sensitive as existing diagnostic tools, with accuracies above 90%. BBMs can be deployed in primary care, enhancing early diagnosis and reducing health disparities.  Lucent Diagnostics, part of Quanterix, is leading this revolution, partnering with global initiatives to implement BBMs in diverse settings. These advancements pave the way for accessible, easily administered tests, enabling early detection and better treatment outcomes. Read more ➡️